SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and DIAGNOS (OTCMKTS:DGNOF – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Risk and Volatility
SOPHiA GENETICS has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, DIAGNOS has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.
Valuation and Earnings
This table compares SOPHiA GENETICS and DIAGNOS”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $86.17 million | 7.93 | -$79.00 million | ($1.15) | -7.08 |
| DIAGNOS | $50,000.00 | 871.25 | -$3.30 million | ($0.04) | -9.00 |
DIAGNOS has lower revenue, but higher earnings than SOPHiA GENETICS. DIAGNOS is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SOPHiA GENETICS and DIAGNOS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -93.86% | -132.47% | -45.97% |
| DIAGNOS | -7,014.89% | N/A | -192.10% |
Analyst Recommendations
This is a summary of current ratings and target prices for SOPHiA GENETICS and DIAGNOS, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
| DIAGNOS | 0 | 0 | 0 | 0 | 0.00 |
SOPHiA GENETICS currently has a consensus target price of $10.00, suggesting a potential upside of 22.85%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, research analysts clearly believe SOPHiA GENETICS is more favorable than DIAGNOS.
Insider and Institutional Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
SOPHiA GENETICS beats DIAGNOS on 10 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}
